The use of botulinum toxin-A in the management of neck and anterior chest wall flushing: pilot study.

Idiopathic neck and chest wall flushing could cause disabling effects on patients' quality of life. We aimed to evaluate the effectiveness of botulinum toxin-A (BTA) in the management of idiopathic neck and chest wall flushing. This was a pilot prospective clinical study of patients with severe idiopathic neck and anterior chest wall flushing. Two mouse units of BTA were injected intracutaneously with a maximum dose of 100 units per patient per session. The dermatology life quality index is used as the primary outcome measure. Twenty-two patients were included in the study (18 women, four men) with an average age of 26 years (range 18-48). Twenty patients (90.9%) had immediate improvement with almost complete resolution of their flushing. At four weeks follow-up, 18 of 22 patients were included in the final analysis, significant improvement in quality of life was achieved, and mean baseline dermatology life quality index score 7.78 (SD 3.25) improved significantly to 4.23 (SD 3.44) with a mean difference of 3.56 (SD 4.6; 95%, confidence interval 1.27, 5.84) with paired samples t-test 3.29 (d.f. 17) P < 0.004. BTA may provide an effective treatment in the management of idiopathic neck and chest wall flushing.

The successful use of botulinum toxin for the treatment of nasal hyperhidrosis.

BACKGROUND: Patients with facial hyperhidrosis often experience occupational, social, and psychological problems. Botulinum toxin type A, which has been shown to be useful in the treatment of hyperhidrosis, can cause the paralysis of facial muscles if used in the skin overlying the facial muscles. It can, however, be used in the skin of the nose without significantly affecting the muscles of facial expression. METHODS: Two patients with severe nasal hyperhidrosis were treated with botulinum toxin. RESULTS: Two patients with severe nasal hyperhidrosis responded to a single session of treatment with intradermal injections of botulinum toxin. CONCLUSIONS: This treatment method for nasal hyperhidrosis is simple, well tolerated, and effective, and significantly improves the quality of life of the affected individuals.

Relationship between vessel size and vascular access patency based on preoperatively ultrasound Doppler.

Vascular access is a critical issue in the management of patients with end-stage renal failure and is the leading cause of hospitalization in this group of patients. The object of this study was to find out whether it would be possible to predict vascular access patency rates based on preoperative Doppler assessment of vessel size. Furthermore, this study sought to define the relationship between access flow rate and access patency. This was a prospective cohort conducted at St. Mary Hospital, London, between 2002 and 2005, where a group of 83 patients who underwent venous and arterial Doppler prior to creation of arteriovenous access underwent regular postoperative assessment at 3-month intervals of their access using flow rate and usability of the access as outcome measures. The collected data showed a positive correlation between vein size and access patency rate. Preoperative vein diameters of 1.5-3.9 mm showed a patency rate of 71.08% at follow-up at 13.8 months (range, 12-42 months). Although large-sized vessels are correlated with long-term patency, smaller vein diameters (1.5-2 mm) were found to have an acceptable patency rate at 20% over 12 months. Furthermore, data indicated a positive correlation between access flow rate and access patency, with flow rates of above 700 ml/min being associated with a patency rate of 70% at 12-month follow-up.